Abstract
Nonalcoholic fatty liver disease (NAFLD) is an increasing public health threat with significant related morbidity and mortality. NAFLD is currently separated into two clinical entities, benign simple steatosis, and NASH, the more progressive form. Instead, NAFLD is likely a spectrum of disease that can progress regardless of the initial histologic findings. Risk factors associated with disease progression of NASH include the histologic findings of lobular inflammation, presence of NASH rather than simple steatosis, and most significant, the presence of fibrosis. In addition, comorbid metabolic conditions such as type 2 diabetes mellitus, obesity, and metabolic syndrome play a significant role in progression, and sometimes regression, of NAFLD. Currently liver biopsy remains the gold standard for diagnosis and staging of NAFLD, however noninvasive testing is garnering more interest in ongoing research trials and will hopefully prove to be a reliable means of evaluating patients with NAFLD in the future.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
